IDIA SW, Updated Analysis, Strong Pipeline Plus Cash for Spinoff, +29% Upside
- Strong Pipeline and Loaded with Cash, Idorsia (IDIA) is Ready to Become a Second Actelion (ATLN)
- For the Parent, Stay on the Sidelines from ATLN (Pre-Spin) Due to Limited Upside
- Spinoff: Investors Recommended to Enter IDIA (Post-Spin) Near CHF7.00 Levels / First Day of Trading June 16, 2017
- Upside (From Tech Split Price): +29% (Base) & +77% (Bull)
- Experienced Management Team, Including CEO Jean-Paul Clozel, Moves to IDIA
- JNJ's Investment in IDIA Reflects Its Confidence in the Spinoff's Drug Pipeline
- The Edge Awaits Spinoff Listing to Evaluate Entry / On Watchlist
Idorsia Ltd. Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.
The Edge Group - Global Fundamental Catalyst Investing. The Edge provides investors with access to hidden corporate value from Global Special Situations using a pioneering approach to investments. Founded in 2005 by fund management and investment banking professionals to provide high quality, private equity-level research on Global Corporate Divestitures for the benefit of fundamental event-driven, growth and value-oriented investors in this difficult to track, but proven investment space.
The Edge will look to screen and analyze include Spinoffs; Reverse Morris Trusts; Squeeze Outs; Privatizations; Demutualization; Deep Discounted; Rights Issues; Rights Offering; Restructuring; Insider Purchases / Buying Change of Management / CEO Change; Deteriorating fundamentals; Post-Bankruptcy; Reorganization; Tender Offer; M&A Deals; Secondary Offering; Share Swap; Thrift Conversions; Share Buybacks; Activist; Mergers. All analyzed from a fundamental point of view.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.